TLR4 and hyperlipidemia: Furthermore, we confirmed that the protective effects of TAK-875 were partially independent of GPR40 expression, and TAK-875 improved the hyperlipidemia-induced metabolic inflammatory injury by inhibiting the metabolic inflammatory pathway TLR4 in vivo.